Cuproptosis-related lncRNA SNHG16 as a biomarker for the diagnosis and prognosis of head and neck squamous cell carcinoma
PeerJ · 2023
DOI: 10.7717/peerj.16197 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2023. Verfasst von Baoai Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, RNA, Long Noncoding, Apoptosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science, Technology and Innovation Seed Fund of Zhongnan Hospital of Wuhan University, Fundamental Research Funds for the Central Universities, Zhongnan Hospital of Wuhan University Excellent Doctor (Postdoctoral) Fund.
Abstract (Originalsprache)
Background
We aim to investigate the potential value of cuproptosis-related lncRNA signaling in predicting clinical prognosis and immunotherapy and its relationship with drug sensitivity in head and neck squamous cell carcinoma (HNSCC).
Methods
We first identified the lncRNAs associated with cuproptosis genes in HNSCC and then conducted a series of analytical studies to investigate the expression and prognostic significance of these lncRNAs. Finally, we used RT-qPCR to validate our findings in a laryngeal squamous cell carcinoma cell line and 12 pairs of laryngeal squamous cell carcinoma and adjacent normal tissues.
Results
We identified 11 differentially expressed lncRNAs that were associated with cuproptosis genes in HNSCC and also served as prognostic markers for this cancer. Enrichment analysis revealed that these lncRNAs were related to immune-related functions that were suppressed in patients with oncogene mutations in the high-risk group. The patients with a high tumor mutation burden exhibited poor overall survival (OS). We used the tumor immune dysfunction and exclusion model to show that the patients in the high-risk group had great potential for immune evasion and less effective immunotherapy. We also identified several drugs that could be effective in treating HNSCC. Experimental validation showed that AC090587.1 and AC012184.3 exhibited differential expression between the TU686 and HBE cell lines, and SNHG16 showed differential expression among the TU686, TU212, and control HBE cells. Among the 12 pairs of cancer and adjacent tissues collected in the clinic, only SNHG16 showed differential expression. Targeted therapy against SNHG16 holds promise as a prospective novel strategy for the clinical management of HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Sleep Medicine Centre, Zhongnan Hospital of Wuhan University, Wuhan, China.
Förderung
- Science, Technology and Innovation Seed Fund of Zhongnan Hospital of Wuhan University
- Fundamental Research Funds for the Central Universities
- Zhongnan Hospital of Wuhan University Excellent Doctor (Postdoctoral) Fund
- Hubei Provincial Natural Science Foundation
Zitieren
APA
Han, B., Li, S., Huang, S., Huang, J., Wu, T., & Chen, X. (2023). Cuproptosis-related lncRNA SNHG16 as a biomarker for the diagnosis and prognosis of head and neck squamous cell carcinoma. PeerJ. https://doi.org/10.7717/peerj.16197
Vancouver
Han B, Li S, Huang S, Huang J, Wu T, Chen X. Cuproptosis-related lncRNA SNHG16 as a biomarker for the diagnosis and prognosis of head and neck squamous cell carcinoma. PeerJ. 2023. doi:10.7717/peerj.16197
BibTeX
@article{Han2023,
author = {Han, Baoai and Li, Shuang and Huang, Shuo and Huang, Jing and Wu, Tingting and Chen, Xiong},
title = {Cuproptosis-related lncRNA SNHG16 as a biomarker for the diagnosis and prognosis of head and neck squamous cell carcinoma},
journal = {PeerJ},
year = {2023},
doi = {10.7717/peerj.16197}
}
EUVIMED